{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T17:29:38Z","timestamp":1771262978164,"version":"3.50.1"},"reference-count":47,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>In patients with myositis, interstitial lung disease (ILD) is one of the major causes of morbidity and mortality. Given the limited evidence, there is an urgent need to refine the treatment for myositis-ILD. This review aims to highlight recent updates on the management of myositis-associated ILD, focusing on screening, risk stratification, and treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Asian race and\/or residence, dermatomyositis, mechanic's hand, antisynthetase antibodies, and antimelanoma differentiation-associated gene 5 antibodies are risk factors for ILD development. Patients with such risk factors should be screened for ILD using high-resolution computed tomography. Various prediction models for mortality or rapidly progressive ILD (RP-ILD) in patients with myositis-ILD have been proposed, but validation of these models in multiple independent studies is required. Academic societies in Japan, the United Kingdom, and the United States have proposed tentative treatment algorithms for myositis-ILD on the basis of the presence or absence of RP-ILD.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Knowledge on myositis-ILD risk stratification, potentially useful for personalized management approaches in clinical practice, is accumulating. However, further global joint efforts are necessary to build a strong evidence base for consensus algorithms for myositis-ILD.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bor.0000000000001037","type":"journal-article","created":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T12:00:28Z","timestamp":1723464028000},"page":"466-472","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["Interstitial lung disease and myositis"],"prefix":"10.1097","volume":"36","author":[{"given":"Takahisa","family":"Gono","sequence":"first","affiliation":[{"name":"Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine"},{"name":"Scleroderma\/Myositis Center of Excellence, Nippon Medical School Hospital, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masataka","family":"Kuwana","sequence":"additional","affiliation":[{"name":"Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine"},{"name":"Scleroderma\/Myositis Center of Excellence, Nippon Medical School Hospital, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2024,8,12]]},"reference":[{"key":"R1-20250526","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/s41572-021-00321-x","article-title":"Idiopathic inflammatory myopathies","volume":"7","author":"Lundberg","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"R2-20250526","doi-asserted-by":"crossref","first-page":"e0155381","DOI":"10.1371\/journal.pone.0155381","article-title":"Factors associated with interstitial lung disease in patients with polymyositis and dermatomyositis: a systematic review and meta-analysis","volume":"11","author":"Zhang","year":"2016","journal-title":"PLoS One"},{"key":"R3-20250526","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.semarthrit.2020.11.009","article-title":"Prevalence of interstitial lung disease in polymyositis and dermatomyositis: a meta-analysis from 2000 to 2020","volume":"51","author":"Sun","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"R4-20250526","doi-asserted-by":"crossref","first-page":"17172","DOI":"10.1038\/s41598-023-44092-9","article-title":"Characteristics and risk of interstitial lung disease in dermatomyositis and polymyositis: a retrospective cohort study in Japan","volume":"13","author":"Hu","year":"2023","journal-title":"Sci Rep"},{"key":"R5-20250526","doi-asserted-by":"crossref","first-page":"152088","DOI":"10.1016\/j.semarthrit.2022.152088","article-title":"The role of myositis-specific autoantibodies and the management of interstitial lung disease in idiopathic inflammatory myopathies: a systematic review","volume":"57","author":"Teel","year":"2022","journal-title":"Semin Arthritis Rheum"},{"key":"R6-20250526","doi-asserted-by":"crossref","first-page":"e332","DOI":"10.1093\/rheumatology\/kead274","article-title":"Mechanic's hands are associated with interstitial lung disease in myositis patients regardless of the presence of antisynthetase antibodies","volume":"62","author":"Bandeira","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"R7-20250526","doi-asserted-by":"crossref","first-page":"103335","DOI":"10.1016\/j.autrev.2023.103335","article-title":"The prevalence and effects of treatments of rapidly progressive interstitial lung disease of dermatomyositis\/polymyositis adults: a systematic review and meta-analysis","volume":"22","author":"Wang","year":"2023","journal-title":"Autoimmun Rev"},{"key":"R8-20250526","doi-asserted-by":"crossref","first-page":"773352","DOI":"10.3389\/fimmu.2021.773352","article-title":"Dermatomyositis with anti-MDA5 antibodies: bioclinical features, pathogenesis and emerging therapies","volume":"12","author":"Nombel","year":"2021","journal-title":"Front Immunol"},{"key":"R9-20250526","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1002\/art.42861","article-title":"2023 American College of Rheumatology (ACR)\/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases","volume":"76","author":"Johnson","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"R10-20250526","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1080\/17476348.2023.2176303","article-title":"Identification and management of connective tissue disease-associated interstitial lung disease: evidence-based Japanese consensus statements","volume":"17","author":"Kuwana","year":"2023","journal-title":"Expert Rev Respir Med"},{"key":"R11-20250526","article-title":"Early detection of interstitial lung disease in rheumatic diseases: a joint statement from the Portuguese Pulmonology Society, the Portuguese Rheumatology Society, and the Portuguese Radiology and Nuclear Medicine Society","author":"Morais","year":"2023","journal-title":"Pulmonology"},{"key":"R12-20250526","doi-asserted-by":"crossref","first-page":"373","DOI":"10.55563\/clinexprheumatol\/brvl1v","article-title":"Myositis-associated interstitial lung disease: a comprehensive approach to diagnosis and management","volume":"40","author":"Hallowell","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"R13-20250526","doi-asserted-by":"crossref","DOI":"10.4081\/reumatismo.2023.1571","article-title":"Diagnosis and treatment of interstitial lung disease related to systemic autoimmune myopathies: a narrative review","volume":"75","author":"De Souza","year":"2023","journal-title":"Reumatismo"},{"key":"R14-20250526","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.3390\/medicina58121757","article-title":"Clinical and radiological features of interstitial lung diseases associated with polymyositis and dermatomyositis","volume":"58","author":"Palmucci","year":"2022","journal-title":"Medicina (Kaunas)"},{"key":"R15-20250526","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.rmed.2011.05.006","article-title":"HRCT features of interstitial lung disease in dermatomyositis with anti-CADM-140 antibody","volume":"105","author":"Tanizawa","year":"2011","journal-title":"Respir Med"},{"key":"R16-20250526","doi-asserted-by":"crossref","first-page":"e003150","DOI":"10.1136\/rmdopen-2023-003150","article-title":"Clinical, radiological and pathological features of anti-MDA5 antibody-associated interstitial lung disease","volume":"9","author":"Chen","year":"2023","journal-title":"RMD Open"},{"key":"R17-20250526","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s10067-023-06816-0","article-title":"Gender differences in patients with anti-MDA5-positive dermatomyositis: a cohort study of 251 cases","volume":"43","author":"Cheng","year":"2024","journal-title":"Clin Rheumatol"},{"key":"R18-20250526","doi-asserted-by":"crossref","first-page":"152350","DOI":"10.1016\/j.semarthrit.2023.152350","article-title":"Serum ferritin as a significant biomarker for patients with idiopathic inflammatory myopathy-associated interstitial lung disease: a systematic review and meta-analysis","volume":"64","author":"He","year":"2024","journal-title":"Semin Arthritis Rheum"},{"key":"R19-20250526","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1186\/s12890-022-02106-8","article-title":"Neutrophil-to-lymphocyte ratio is a predictive marker for anti-MDA5 positive dermatomyositis","volume":"22","author":"Liu","year":"2022","journal-title":"BMC Pulm Med"},{"key":"R20-20250526","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/BOR.0000000000000905","article-title":"Biomarkers of disease activity in dermatomyositis","volume":"34","author":"Lu","year":"2022","journal-title":"Curr Opin Rheumatol"},{"key":"R21-20250526","doi-asserted-by":"crossref","first-page":"e24726","DOI":"10.1002\/jcla.24726","article-title":"Roles of biomarkers in anti-MDA5-positive dermatomyositis, associated interstitial lung disease, and rapidly progressive interstitial lung disease","volume":"36","author":"Li","year":"2022","journal-title":"J Clin Lab Anal"},{"key":"R22-20250526","doi-asserted-by":"crossref","first-page":"117443","DOI":"10.1016\/j.cca.2023.117443","article-title":"Polymyositis and dermatomyositis biomarkers","volume":"547","author":"Xu","year":"2023","journal-title":"Clin Chim Acta"},{"key":"R23-20250526","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/crj.13616","article-title":"Soluble CD206 levels correlate with disease deterioration and predict prognosis of anti-MDA5 antibody-positive dermatomyositis related interstitial lung disease","volume":"17","author":"Li","year":"2023","journal-title":"Clin Respir J"},{"key":"R24-20250526","doi-asserted-by":"crossref","first-page":"107530","DOI":"10.1016\/j.rmed.2024.107530","article-title":"Hypouricemia as a novel predictor of mortality in anti-MDA5 positive dermatomyositis patients with ILD: a retrospective cohort study","volume":"222","author":"Liu","year":"2024","journal-title":"Respir Med"},{"key":"R25-20250526","first-page":"373","article-title":"A systematic review and metaanalysis of predictors of mortality in idiopathic inflammatory myopathy-associated interstitial lung disease","volume":"50","author":"Hannah","year":"2023","journal-title":"J Rheumatol"},{"key":"R27-20250526","doi-asserted-by":"crossref","first-page":"4570","DOI":"10.1093\/rheumatology\/keac090","article-title":"Anti-Ro52 antibodies are associated with the prognosis of adult idiopathic inflammatory myopathy-associated interstitial lung disease","volume":"61","author":"Gui","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"R28-20250526","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3899\/jrheum.220139","article-title":"Coexistence of anti-Ro52 antibodies in anti-MDA5 antibody-positive dermatomyositis is highly associated with rapidly progressive interstitial lung disease and mortality risk","volume":"50","author":"Lv","year":"2023","journal-title":"J Rheumatol"},{"key":"R29-20250526","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s13075-023-03100-z","article-title":"Mortality risk in patients with anti-MDA5 dermatomyositis is related to rapidly progressive interstitial lung disease and anti-Ro52 antibody","volume":"25","author":"Wang","year":"2023","journal-title":"Arthritis Res Ther"},{"key":"R30-20250526","doi-asserted-by":"crossref","first-page":"e002076","DOI":"10.1136\/bmjresp-2023-002076","article-title":"Association of anti-Ro52 autoantibody with interstitial lung disease in autoimmune diseases: a systematic review and meta-analysis","volume":"10","author":"Nayebirad","year":"2023","journal-title":"BMJ Open Respir Res"},{"key":"R31-20250526","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.3390\/diagnostics13243621","article-title":"Dissociating autoantibody responses against Ro52 antigen in patients with anti-synthetase or anti-MDA5 antibodies","volume":"13","author":"Yoshida","year":"2023","journal-title":"Diagnostics (Basel)"},{"key":"R32-20250526","doi-asserted-by":"crossref","first-page":"152407","DOI":"10.1016\/j.semarthrit.2024.152407","article-title":"The differential role of SSa\/SSb and Ro52 antibodies in defining clinical phenotypes in idiopathic inflammatory myopathies","volume":"65","author":"Valle","year":"2024","journal-title":"Semin Arthritis Rheum"},{"key":"R33-20250526","doi-asserted-by":"crossref","first-page":"e1085","DOI":"10.1002\/iid3.1085","article-title":"Clinical characteristics and prognostic analysis of idiopathic inflammatory myopathy with positive antiaminoacyl-tRNA synthetase antibodies: a single center experience","volume":"11","author":"Zhang","year":"2023","journal-title":"Immun Inflamm Dis"},{"key":"R34-20250526","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1002\/art.42785","article-title":"Prognostic role of interferon-\u03bb3 in anti-melanoma differentiation-associated gene 5-positive dermatomyositis-associated interstitial lung disease","volume":"76","author":"Fukada","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"R35-20250526","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1212\/WNL.0000000000009727","article-title":"Different phenotypes in dermatomyositis associated with anti-MDA5 antibody: study of 121 cases","volume":"95","author":"Allenbach","year":"2020","journal-title":"Neurology"},{"key":"R36-20250526","doi-asserted-by":"crossref","first-page":"883699","DOI":"10.3389\/fmed.2022.883699","article-title":"Mortality risk stratification using cluster analysis in patients with myositis-associated interstitial lung disease receiving initial triple-combination therapy","volume":"9","author":"Gono","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"R37-20250526","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/art.42308","article-title":"Identification of three different phenotypes in anti-Melanoma differentiation-associated Gene 5 antibody-positive dermatomyositis patients: implications for prediction of rapidly progressive interstitial lung disease","volume":"75","author":"Xu","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"R38-20250526","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1002\/art.41566","article-title":"Risk prediction modeling based on a combination of initial serum biomarker levels in polymyositis\/dermatomyositis-associated interstitial lung disease","volume":"73","author":"Gono","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"R39-20250526","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/j.chest.2020.04.057","article-title":"Mortality risk prediction in amyopathic dermatomyositis associated with interstitial lung disease: the FLAIR Model","volume":"158","author":"Lian","year":"2020","journal-title":"Chest"},{"key":"R40-20250526","doi-asserted-by":"crossref","first-page":"978708","DOI":"10.3389\/fimmu.2022.978708","article-title":"Prediction model for the pretreatment evaluation of mortality risk in antimelanoma differentiation-associated gene 5 antibody-positive dermatomyositis with interstitial lung disease","volume":"13","author":"Gui","year":"2022","journal-title":"Front Immunol"},{"key":"R41-20250526","doi-asserted-by":"crossref","first-page":"908365","DOI":"10.3389\/fmed.2022.908365","article-title":"A new predictive model for the prognosis of MDA5","volume":"9","author":"Niu","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"R42-20250526","doi-asserted-by":"crossref","first-page":"860798","DOI":"10.3389\/fmed.2022.860798","article-title":"A matrix prediction model for the 6-month mortality risk in patients with anti-melanoma differentiation-associated protein-5-positive dermatomyositis","volume":"9","author":"Ouyang","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"R43-20250526","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.1093\/rheumatology\/keac094","article-title":"Predictors of rapidly progressive interstitial lung disease and mortality in patients with autoantibodies against melanoma differentiation-associated protein 5 dermatomyositis","volume":"61","author":"So","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"R44-20250526","doi-asserted-by":"crossref","first-page":"1286973","DOI":"10.3389\/fimmu.2024.1286973","article-title":"Rapidly progressive interstitial lung disease risk prediction in anti-MDA5 positive dermatomyositis: the CROSS model","volume":"15","author":"Wang","year":"2024","journal-title":"Front Immunol"},{"key":"R45-20250526","doi-asserted-by":"crossref","first-page":"e940251","DOI":"10.12659\/MSM.940251","article-title":"Risk prediction for rapidly progressive interstitial lung disease in anti-MDA5-positive dermatomyositis: the CRAFT Model","volume":"29","author":"Guo","year":"2023","journal-title":"Med Sci Monit"},{"key":"R46-20250526","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1093\/rheumatology\/kead263","article-title":"A nomogram based on clinical factors and CT radiomics for predicting anti-MDA5+ DM complicated by RP-ILD","volume":"63","author":"Li","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"R47-20250526","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.resinv.2021.04.011","article-title":"2020 guide for the diagnosis and treatment of interstitial lung disease associated with connective tissue disease","volume":"59","author":"Kondoh","year":"2021","journal-title":"Respir Investig"},{"key":"R48-20250526","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1093\/rheumatology\/keac115","article-title":"British Society for Rheumatology guideline on management of paediatric, adolescent and adult patients with idiopathic inflammatory myopathy","volume":"61","author":"Oldroyd","year":"2022","journal-title":"Rheumatology (Oxford)"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000001037","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T21:18:27Z","timestamp":1748294307000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000001037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,12]]},"references-count":47,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000001037","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,12]]}}}